resiquimod has been researched along with Adenocarcinoma, Basal Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caisova, V; Chlastakova, A; Chmelar, J; Frejlachova, A; Hansen, P; Kopecky, J; Kvardova, K; Lencova, R; Masakova, K; Pacak, K; Padoukova, L; Skalickova, M; Uher, O; Venhauerova, A; Zenka, J; Zhuang, Z | 1 |
| Caisová, V; Chmelař, J; Jochmanová, I; Kopecký, J; Krejčová, G; Kvardová, K; Masáková, K; Nedbalová, P; Paďouková, L; Uher, O; Ženka, J | 1 |
2 other study(ies) available for resiquimod and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; CD40 Antigens; Imidazoles; Immunotherapy; Ligands; Lipopolysaccharides; Mannans; Mice; Pancreatic Neoplasms; Poly I-C; T-Lymphocytes; Teichoic Acids; Toll-Like Receptors | 2021 |
Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Female; Imidazoles; Immunotherapy; Lipopolysaccharides; Lymphocytes, Tumor-Infiltrating; Mannans; Melanoma, Experimental; Mice, Inbred C57BL; Neutrophils; Pancreatic Neoplasms; Phagocytosis; Poly I-C; Teichoic Acids; Toll-Like Receptors; Tumor Burden | 2018 |